WO2003030920A9 - Nouveau medicament anti-asthmatique (asmakure) a base d'herbes indigenes permettant de soigner l'asthme - Google Patents

Nouveau medicament anti-asthmatique (asmakure) a base d'herbes indigenes permettant de soigner l'asthme

Info

Publication number
WO2003030920A9
WO2003030920A9 PCT/IN2002/000203 IN0200203W WO03030920A9 WO 2003030920 A9 WO2003030920 A9 WO 2003030920A9 IN 0200203 W IN0200203 W IN 0200203W WO 03030920 A9 WO03030920 A9 WO 03030920A9
Authority
WO
WIPO (PCT)
Prior art keywords
delivery system
oxybutynin
drug delivery
pharmaceutically acceptable
release composition
Prior art date
Application number
PCT/IN2002/000203
Other languages
English (en)
Other versions
WO2003030920A1 (fr
Inventor
Dilip Shantilal Shanghvi
Ashish Prabhakar Mungre
Yashoraj Rupsinh Zala
Original Assignee
Sun Pharmaceutical Ind Ltd
Dilip Shantilal Shanghvi
Ashish Prabhakar Mungre
Yashoraj Rupsinh Zala
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IN2002/000107 external-priority patent/WO2002080887A2/fr
Priority to AU2002356418A priority Critical patent/AU2002356418A1/en
Priority to EP02800696A priority patent/EP1450783A1/fr
Priority to CA002463168A priority patent/CA2463168A1/fr
Priority to BR0213634-1A priority patent/BR0213634A/pt
Priority to US10/492,070 priority patent/US20040265381A1/en
Application filed by Sun Pharmaceutical Ind Ltd, Dilip Shantilal Shanghvi, Ashish Prabhakar Mungre, Yashoraj Rupsinh Zala filed Critical Sun Pharmaceutical Ind Ltd
Priority to HU0402611A priority patent/HUP0402611A2/hu
Priority to KR10-2004-7005049A priority patent/KR20040045485A/ko
Priority to JP2003533951A priority patent/JP2005510477A/ja
Priority to MXPA04003002A priority patent/MXPA04003002A/es
Publication of WO2003030920A1 publication Critical patent/WO2003030920A1/fr
Publication of WO2003030920A9 publication Critical patent/WO2003030920A9/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Definitions

  • the present invention relates to an antispasmodic agent spaced drug delivery system that provides spaced drug delivery of oxybutynin wherein oxybutynin is released in a pulse initially and then at one or more predetermined time intervals.
  • Oxybutynin chloride [ ⁇ -cyclohexyl- ⁇ -hydroxybenzeneacetic acid 4-(diethylamino)-2- butynyl ester hydrochloride] disclosed in the British Patent No. 940,540 and United States Patent No. 4870074 is a musculotropic antispasmodic drug with moderate anticholinergic, systemic analgesic and local anaesthetic action. Its relaxant effect on smooth muscle is based on antagonism of a process distal to the neuromuscular junction (papaverine-like effect) and on anticholinergic action on the blockage of muscarine-type receptors. Oxybutynin chloride has been in clinical use for twenty years and it is indicated for the relief of symptoms associated with voiding in patients with an uninhibited neurogenic and reflex neurogenic bladder.
  • Oxybutynin is rapidly absorbed from the gastrointestinal tract following oral administration and its phamiacological action starts within one hour.
  • the duration of action of the drug is three to six hours. It has a half-life of less than 2 hours.
  • the usual dose in the management of incontinence is repeated doses of 5 mg tablets from two-to- four times a day. This is difficult to achieve as it requires rigid patient compliance and also it is cost ineffective.
  • United States Patent No. 3,247,066 claims a controlled release dosage form comprising a solid bead covered by a rupturable plastic, non-toxic, insoluble, non- digestible film coating which is inert to the gastrointestinal fluid and permeable to diffusion of water, the bead containing a uniform dispersion of the medicament in a water-swellable colloid, the thickness of the coating and swellability of the bead being such that on prolonged exposure to gastrointestinal fluid, diffusion of water takes place through the coating into the bead, causing the bead to swell up and build up pressure exceeding the cohesive strength of the coating thereby resulting in outward rupture of the coating and release of the medicament from the bead into the gastrointestinal fluid.
  • the swellable colloid used is gelatin that exhibits only a small to moderate degree and rate of swelling and fails to provide the formulator a desired degree of swelling to cause the release to occur as a pulse at about a predetermined time period. Also the patent does not suggest the use of antispasmodics as a therapeutic class, in the subject invention.
  • United States Patent No. 5,654,009 discloses an intramuscularly or subcutaneously administered delayed action preparation comprising a core portion containing the drug and a hydratable swelling polymer, and an outer membrane of a biodegradable high molecular weight substance surrounding the core.
  • the water penetrating, through the outer layer into the core causes swelling of the hydratable swelling polymer present in the core, thereby causing an explosion of the outer membrane.
  • This system claims an improvement over prior art in that it is capable of causing the outer membrane to explode at a predetermined time.
  • the system of the '009 patent is neither particularly meant to nor is it capable of releasing the drug thereafter at a rapid rate when desired.
  • the patent does not suggest the use of antispasmodics as a therapeutic class, in the subject invention.
  • United States Patent No. 5840754 discloses a method of lessening the incidence of side- effects in a patient comprising administering oxybutynin tablet dosage form that can deliver oxybutynin over 24 hours to the patient at a substantially controlled and sustained rate to provide control on desired plasma oxybutynin concentration and reduce peak plasma concentration.
  • the patent teaches a person skilled in the art that pulse release of oxybutynin would be undesirable.
  • a spaced drug delivery system for oxybutynin or its pharmaceutically acceptable salts comprising (a) an immediate release composition releasing oxybutynin or its pharmaceutically acceptable salts immediately initially and (b) timed pulse release composition(s) releasing oxybutynin or its pharmaceutically acceptable salts in a pulse at one or more predetermined time intervals.
  • the spaced drug delivery system is suitable for twice-a-day or once-a-day therapy of urinary incontinence.
  • an antispasmodic agent spaced drug delivery system capable of programmed delivery or release in a predetermined number of pulses of predetermined amounts of oxybutynin at spaced predetermined time intervals for optimum therapy of urinary incontinence.
  • Figure 1 shows the plasma concentration vs time profile obtained upon administration of an embodiment of the spaced drug delivery system of oxybutynin chloride of the present invention in comparison to commercially available Ditropan XL tablets.
  • the present invention discloses a novel concept of spaced drug delivery system for oxybutynin.
  • the spaced drug delivery system of the present invention can be administered in a single dose to the patient to provide therapeutically effective plasma levels of oxybutynin over a period of 12 hours to 24 hours by delivering at spaced time intervals the oxybutynin in pulses. The need for the patient to take multiple dosages during this interval is obviated.
  • the present invention specifically provides an antispasmodic agent spaced drug delivery system comprising an immediate release composition releasing oxybutynin immediately as a pulse and one or more timed pulse release composition(s) releasing oxybutynin in a pulse at predetermined time intervals.
  • the present invention provides an antispasmodic agent spaced drug delivery system comprising;
  • a timed pulse release composition releasing oxybutynin or its pharmaceutically acceptable salts in a pulse at about a predetermined time
  • the spaced drug delivery system of the present invention comprises therapeutically effective amount of oxybutynin for twice-a-day or once-a-day therapy.
  • oxybutynin chloride may be present in amounts in the range from about 2.5 mg to 30 mg, more preferably from about 5 mg to 15 mg.
  • the oxybutynin amount may be the same in the immediate release and the timed pulse release compositions.
  • a spaced drug delivery system comprising 15 mg oxybutynin chloride; 5 mg may be present in the immediate release composition, 5 mg may be present in a first timed pulse release composition releasing the 5 mg at a first predetermined time and 5 mg may be present in a second timed pulse release composition releasing the 5 mg at a second predeterniined time.
  • the oxybutynin amount may be different in the immediate release and the timed pulse release compositions.
  • a spaced drug delivery system comprising 10 mg oxybutynin chloride; 2.5 mg may be present in the immediate release composition, 4 mg may be present in a first timed pulse release composition releasing the 4 mg at a first predetermined time and 3.5 mg may be present in a second timed pulse release composition releasing the 3.5 mg at a second predetermined time.
  • the spaced drug delivery system can be designed to release predetermined amounts of oxybutynin as a pulse initially and then at predetermined time intervals to provide optimum therapy.
  • the number of pulses of oxybutynin release can also be selected to optimize the therapy.
  • the spaced drug delivery system of the present invention thus provides ease and flexibility in providing desired plasma levels of oxybutynin for optimum therapy.
  • Immediate release compositions are well known in the art and the immediate release composition of the spaced drug delivery system of the present invention maybe provided according to the known art.
  • the timed pulse release composition may be provided using known art but preferably the composition is provided in accordance with preferred embodiments of the present invention as described herein below.
  • the preferred antispasmodic agent spaced drug delivery system of the present invention comprises;
  • a timed pulse release composition comprising a core comprising oxybutynin or its pharmaceutically acceptable salts, a swelling agent that swells to at least twice its volume upon imbibing water from the environment, and optionally, water-soluble compound(s) for inducing osmosis; and a coat surrounding the core wherein the coat comprises coating agents selected and used in amounts such that the coat ruptures or bursts to release in a pulse, the oxybutynin or its pharmaceutically acceptable salts at about a predetermined time; and
  • timed pulse release composition(s) as defined in (b) above, but which release(s) oxybutynin or its pharmaceutically acceptable salts in a pulse at about a predetermined time which is different than that of the timed pulse release composition defined in (b).
  • the preferred timed pulse release composition of the present invention comprising a core comprising oxybutynin or its pharmaceutically acceptable salts, a swelling agent, optionally, water-soluble compounds for inducing osmosis and a coat surrounding the core, is provided, wherein upon imbibing fluid from the surrounding the core swells, and the coat ruptures or bursts to release in a pulse, the oxybutynin or its pharmaceutically acceptable salts at about a predetermined time.
  • the coat of the preferred timed pulse release composition of the present invention ruptures in a reliable manner.
  • release in a pulse refers to release characteristic of conventional tablets and capsules that are devoid of design characteristics that result in slow, extended, controlled or retarded release of the therapeutically active agent when tested by standard in-vitro testing methods.
  • the "release of oxybutynin or its pharmaceutically acceptable salts in a pulse” comprises release, of not more than 10% of the active ingredient at 3 hours and 45 min and at least 70% of the active ingredient at 2 hrs after the coat ruptures or bursts, which is about 6 hours after the start of the dissolution test, when tested by subjecting the tablets to USP dissolution test using pH 4.5 acetate buffer at 37 ⁇ 0.5 ° C, in a USP Type ⁇ apparatus at an rpm of 50.
  • the swelling agent that may be used in the preferred composition of the present invention is selected from hydrophilic polymers.
  • the hydrophilic polymers may be of plant, animal, mineral or synthetic origin. Suitable swellable polymers for use in the present invention include (A) cellulose derivatives such as C ⁇ - 4 alkyl celluloses like methyl cellulose and ethyl cellulose; hydroxy C ⁇ - alkyl celluloses such as hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and the like; hydroxy C ⁇ - alkyl C ⁇ - 4 alkyl celluloses such as hydroxypropyl methylcellulose, hydroxypropyl ethylcellulose and the like; carboxy C ⁇ - 4 alkyl celluloses such as carboxymethyl cellulose, carboxyethyl cellulose, and their alkali salts; and the like, (B) vinylpyrrolidone polymers such as polyvinyl pyrrolidone, crosslinked polyvinyl pyrrolidone or
  • the swelling agent that may be used in the present invention may comprise one or more swellable hydrophilic polymers.
  • the quantity or relative proportion of the polymers is subject to considerable variation. However, a sufficient quantity of the material is present in the core to provide, upon uptake of water, a swelling pressure in excess of the cohesive strength of the coating surrounding the tablet or core.
  • the polymers are employed in the dry state or in a fom that has substantial capacity for water uptake.
  • swellable hydrophilic polymers that may be used in the timed pulse release composition of the present invention as the swelling agent include vinylpyrrolidone polymers such as povidone, or crosslmked polyvinylpyrrolidone such as crospovidone;
  • the swelling agent used comprises a swelling agent that swells considerably but does not form a strong gel, and may be selected from the group comprising crosslinked sodium carboxymethyl cellulose, crosslinked polyvinylpyrrolidone and sodium starch glycolate.
  • the alkali salt of crosslinked carboxyalkyl cellulose i.e. crosslinked sodium carboxymethyl cellulose, also known as croscarmellose sodium or Ac-Di-Sol, is available commercially as Nymcel ® ZSX, Pharmacel ® XL, Primellose ® or Solutab ® .
  • the amount of swelling agent that may be used is dependent on the desired time of rupture of the timed pulse release coat, nature and amounts of other components in the core, as well as the composition and thickness of the coat.
  • croscarmellose sodium may be used as the polymeric swelling agent in an amount ranging from about 1% to about 95% by weight of the core, preferably from about 2% to about 40% by weight of the core, more preferably from about 5% to about 20% by weight of the core.
  • Vinyl pyrrolidone polymers or polyvinyl pyrrolidone (PVP), also referred to as Povidone, are synthetic polymers consisting essentially of linear l-vinyl-2-pyrrolidinone groups, the degree of polymerization of which results in polymers of various molecular weights, the molecular weight ranging between 2500 and 3,000,000 Daltons.
  • PNP is commercially available as Kollidon ® (BASF), Plasdone ® and Peristone ® (General Aniline). PNP is classified into different grades on the basis of its viscosity in aqueous solution.
  • PNP K-12, PVP K-15, PVP K-17, PVP K-25, PVP K-30, PVP K-60, PVP K-90 and PVP K-120 are PNP K-12, PVP K-15, PVP K-17, PVP K-25, PVP K-30, PVP K-60, PVP K-90 and PVP K-120.
  • the K-value referred to in the above nomenclature is calculated from the viscosity of the PVP in aqueous solution, relative to that of water.
  • Crospovidone or cross-PVP the synthetic crosslinked homopolymer of ⁇ - vinyl-2-pyrrolidinone, may also be used as a swellable hydrophilic polymer. It is commercially available as Kollidon CL and Polyplasdone XL, and has a molecular weight higher than 1,000,000 Daltons.
  • Crospovidone may be used as the swellable hydrophilic polymers in an amount ranging from about 2% to about 5% by weight of the core.
  • the preferred vinyl pyrrolidone polymer for use as a swellable hydrophilic polymer is PVP K-30, having an approximate molecular weight of 50,000 Daltons. It may be used in an amount ranging from about 0.5% to about 5% by weight of the core, more preferably from about 1% to about 2% by weight of the core.
  • Sodium starch glycolate the sodium salt of carboxymethyl ether of starch, may also be used as the polymeric swelling agent. It has a molecular weight ranging between 500,000 and 1,000,000 Daltons, and is commercially available as Explotab and Primojel.
  • Sodium starch glycolate may be used in the present invention in an amount ranging from about 0.5% to about 40% by weight of the core, preferably from about 2% to about 40% by weight of the core, more preferably from about 2% to about 10% by weight of the core.
  • the core in the timed pulse release composition contains a wicking agent.
  • wicking agent as used herein implies a broader definition than a conventional wicking agent and includes any pharmaceutical excipient that provides influx of water into the core by any suitable mechanism, preferably by capillary action as is typical of conventional wicking agents.
  • Materials suitable for use as wicking agents in the timed pulse release composition include, but are not limited to, colloidal silicon dioxide, kaolin, titanium dioxide, fumed silicon dioxide, alumina, sodium lauryl sulfate, microcrystalline cellulose, low molecular weight polyvinyl pyrrolidone, bentonite, magnesium aluminum silicate, and the like.
  • the timed pulse release composition of the antispasmodic agent spaced drug delivery system of the present invention may be optimized to obtain the reliable manner of rupture without the use of a wicking agent.
  • the use of a wicking agent has been found to be useful to make the task of optimization to obtain the reliable manner of rupture easier.
  • Microcrystalline cellulose (MCC) used in the preferred embodiment as the wicking agent is made up of a chain of about 250 glucose molecules in the form of a microcrystal, consisting primarily of crystallite aggregates obtained by removing amorphous regions of a pure cellulose source material by hydrolytic degradation using mineral acid.
  • MCC has an average molecular weight of about 36,000 Daltons and is available in various grades, which differ in bulk density, particle size and moisture content. It is commercially available as Vivapur ® , Avicel ® , Vivacel ® , Emcocel ® , Fibrocel ® and Tabulose ® .
  • Avicel ® PH 101 having a mean particle size of 50 ⁇ m, i.e.
  • 1% or less of the particles are retained on a # 60 sieve (as defined by ASTM, American Society for Testing and Materials), and 30%) or less of the particles are retained on a # 200 sieve (as defined by ASTM), and having a moisture content 5% and Avicel ® PH 102, having a mean particle size of lOO ⁇ m, i.e. 8% or less of the particles are retained on a # 60 sieve (as defined by ASTM, American Society for Testing and Materials), and 45% or more of the particles are retained on a # 200 sieve (as defined by ASTM), and having a moisture content of 5%, are used in more preferred embodiments of the timed pulse release composition.
  • the wicking agent comprises a mixture of microcrystalline cellulose (MCC) and colloidal silicon dioxide, h preferred embodiments of the present invention made by granulation techniques, MCC is added intragranularly and extragranularly wherein it is present in an amount ranging from about 30% to about 90% by weight of the core, more preferably about 40% to about 60% by weight of the core intragranularly and is present along with colloidal silicon dioxide extragranularly preferably in an total amount ranging from about 1% to about 10% by weight of the core, more preferably about 2% to about 5% by weight of the core.
  • MCC microcrystalline cellulose
  • colloidal silicon dioxide extragranularly preferably in an total amount ranging from about 1% to about 10% by weight of the core, more preferably about 2% to about 5% by weight of the core.
  • Water-soluble compounds suitable for inducing osmosis i.e. osmotic agents or osmogents are generally used in the core of the timed pulse release composition when the drug itself does not exert sufficient osmotic pressure in order to imbibe fluid from the surroundings.
  • Osmogents that may be present in the core of the timed pulse release composition include all pharmaceutically acceptable and pharmacologically inert water- soluble compounds referred to in the pharmacopoeias such as United States Pharmacopoeia, as well as in Remington: The Science and Practice of Pharmacy, edition 20, Lippincott Williams and Wilkins, Philadelphia (2000).
  • Pharmaceutically acceptable water-soluble salts of inorganic or organic acids, or non-ionic organic compounds with high water solubility are generally preferred.
  • agents used for inducing osmosis include inorganic salts such as magnesium chloride or magnesium sulfate, lithium, sodium or potassium chloride, lithium, sodium or potassium hydrogen phosphate, lithium, sodium or potassium dihydrogen phosphate, salts of organic acids such as sodium or potassium acetate, magnesium succinate, sodium benzoate, sodium citrate or sodium ascorbate; carbohydrates such as mannitol, sorbitol, arabinose, ribose, xylose, glucose, fructose, mannose, galactose, sucrose, maltose, lactose, raffinose; water-soluble amino acids such as glycine, leucine, alanine, or methionine; urea and the like, and mixtures thereof.
  • the amount of os include inorganic salts such as magnesium chloride or magnesium
  • the core of the timed pulse release composition may optionally contain pharmaceutically acceptable excipients such as binders, disintegrants, lubricants and the like.
  • pharmaceutically acceptable excipients such as binders, disintegrants, lubricants and the like.
  • binders commonly include starch, gelatin, sugars like sucrose, glucose, dextrose, molasses and lactose; acacia, sodium alginate, cellulose derivatives like methyl cellulose, ethyl cellulose, carboxymethyl cellulose and the like; polymers such as polyvinyl pyrrolidone, Veegum, polyethylene glycol, waxes and the like.
  • lubricants examples include talc, magnesium stearate, calcium stearate, aluminium stearate, stearic acid, hydrogenated vegetable oils, colloidal silicon dioxide, polyethylene glycol, cellulose derivatives such as carboxyalkyl cellulose and its alkali salts, or mixtures thereof. Hydrophobic or water insoluble lubricants may reduce the water imbibing properties of the core whereas hydrophilic or water soluble lubricants do not, and are preferred. A more preferred lubricant is colloidal silicon dioxide. A mixture of colloidal silicon dioxide and magnesium stearate may be used as the preferred lubricant.
  • More ' preferred embodiments use a combination of microcrystalline cellulose and colloidal silicon dioxide as the .wicking agents, with colloidal silicon dioxide also functioning as a lubricant.
  • Colloidal silicon dioxide is available commercially as Aerosil ® from Degussa- Huls, Nippon and Fischer GmbH.
  • the preferred colloidal silicon dioxide lubricant is Aerosil ® 200, with an approximate external surface area of 200m 2 /g.
  • the colloidal silica may be used in amounts in the range of about 0.5 % to about 5% by weight of the core.
  • the coat surrounding the core is substantially impermeable to the drug and does not release substantial amount of the drug, until it ruptures or bursts at a predetermined time after oral administration of the delivery system.
  • the coating agents that may be used in the present invention are selected from among water insoluble polymers, hydrophobic compounds, hydrophilic non-polymeric compounds and hydrophilic polymers that may be of plant, animal, mineral or synthetic origin.
  • Suitable coating agents include among others cellulose derivatives such as cellulose acetate phthalate, hydroxypropyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl ethylcellulose, ethyl cellulose, methyl cellulose, microcrystalline cellulose, carrageenan, or mixtures thereof, and the like; methacrylic acid and methacrylate esters such as anionic and cationic polymers of methacrylic acid, copolymers of methacrylates, copolymers of acrylates and methacrylates, copolymers of ethacrylate and methylmethacrylate, polyvinylacetate phthalate, waxes such as beeswax, carnauba wax, and the like, glyceryl monostearate, stearic acid, palmitic acid, glyceryl monopalmitate, cetyl alcohol and the like, or mixtures thereof.
  • cellulose derivatives such as cellulose acetate phthalate, hydroxypropyl methylcellulose
  • coating agent as used herein also includes plasticizers that are used in coating compositions and are known to those skilled in the art.
  • the plasticizer may be a low molecular weight compound or may itself be a polymer.
  • the coating agent comprises a mixture of atleast two coating agents.
  • the time of release of oxybutynin or its pharmaceutically acceptable salts from the timed release composition may be varied by varying the ratio of the two or more coating agents.
  • the coating agent is a mixture of a water insoluble polymer and a water soluble compound selected from a water soluble plasticizer and water soluble polymer.
  • a mixture of ethyl cellulose and hydroxypropyl methylcellulose (HPMC) is used as the coating agent.
  • the ethyl cellulose and hydroxypropyl methylcellulose is used in mixture in a ratio suitable to cause opening of the coat at a predetermined time after oral administration of the delivery system.
  • the two polymers ethyl cellulose: hydroxypiOpyl methylcellulose may be preferably used in ratios from about 0:20 to about 20:0 of ethyl cellulose : hydroxypropyl methylcellulose, more preferably the two polymers may be used in ratios from about 4:1 to about 2:1 of ethyl cellulose : hydroxypropyl methylcellulose.
  • a more preferred embodiment of the present invention is in the form of a spaced drug delivery system comprising an immediate release composition that releases oxybutynin or its pharmaceutically acceptable salts within 30 minutes after oral administration, a first timed pulse release composition that releases oxybutynin or its pharmaceutically acceptable salt in a pulse at about a predetermined time after oral administration wherein the time of release lies in the range of 3 to 6 hours, and a second timed pulse release composition that releases oxybutynin or its pharmaceutically acceptable salt in a pulse at about a predetermined time after oral administration wherein the time of release lies in the range of 6 to 10 hours.
  • the amounts of oxybutynin released at 0 hours, 3 to 6 hours and 6 to 10 hours may at each of these times of release represent 33.33 % by weight of the total amount of oxybutynin in the spaced drug delivery system.
  • the amounts of oxybutynin released at 0 hours, 3 to 6 hours and 6 to 10 hours may at each of these times of release represent 25 %, 40 % and 35 % by weight of the total amount of oxybutynin in the spaced drug delivery system.
  • the core of the timed pulse release composition comprises of the following:
  • the core of the above timed pulse release composition as in Table 1 may be surrounded by a coat comprising of coating agent comprising a mixture of ethyl cellulose : hydroxypropyl methylcellulose in the ratios by weight of 4 : 1 to 2 : 1, most preferably 3 : 1.
  • the coating agent may be added in an amount from about 12 to 15 % by weight of the core to release the oxybutynin or its pharmaceutically acceptable salts in a pulse at about 4 hours.
  • the coating agent may be added in an amount from about 18 to 22 % by weight of the core to release oxybutynin or its pharmaceutically acceptable salts in a pulse at about 8 hours.
  • the spaced drug delivery system for oxybutynin or its pharmaceutically acceptable salts comprise the immediate release composition, a first timed pulse release composition providing pulse release at 4 hours and a second timed pulse release composition providing pulse release at 8 hours.
  • the antispasmodic agent spaced drug delivery system of the present invention may be prepared by methods well known to those skilled in the art.
  • the timed pulse release composition may be prepared in the form of coated tablets or coated pellets or coated granules by conventional means known in the art.
  • the immediate release composition may be prepared by conventional means known in the art as a separate physical component of the system, for example separate or physically distinct particles, granules, beads or tablets.
  • the immediate release composition may be in the form of a layer associated with the timed pulse release composition either as a laminar layer or as a layer that surrounds the timed pulse release coat.
  • composition When the composition is present as a layer or coat over the timed pulse release core, it is formed by conventional techniques known to a person skilled in the art such as powder layering and compression coating.
  • the active ingredient(s) may alternatively be dissolved in a suitable solvent and sprayed on the coated core to form the immediate release layer.
  • the antispasmodic agent spaced drug delivery system of the present invention was prepared as per the formula in Table 2 below.
  • the cores for the immediate release tablets, tablets releasing oxybutynin at a predetermined time of 4 hours and the tablets releasing oxybutynin at a predetermined time of 8 hrs were prepared by the method of preparation as described herewith.
  • Oxybutinin chloride, Avicel PH 101, lactose monohydrate and croscarmellose sodium were sifted through a suitable sieve and mixed in a rapid mixer granulator.
  • the dry powder blend was then granulated using 10 % starch paste, followed by wet milling the mass through a fitz mill.
  • the granules so obtained were dried to moisture content of 3- 4%.
  • the dry granules were then milled in a fitz mill through a 1.55 mm screen, followed by sifting of the granules through a #16 sieve (as defined by American Society for Testing and Materials, ASTM). These granules of oxybutynin chloride were then mixed with Avicel PH 102, colloidal silicon dioxide and magnesium stearate and the lubricated mixture thus obtained was compressed on a rotary compression machine using round shaped punches.
  • the immediate release tablet cores were not coated while the tablet cores for releasing the drug at a predetermined time intervals were coated using the coating composition given in Table 3 below.
  • the core tablets were coated in a conventional coating pan using a solution of ethylcellulose and HPMC E50 in a mixture of dichloromethane and methanol.
  • the tablets that release oxybutynin at predetermined time of about 4 hours could be obtained when the tablets were coated to a weight gain of 13-14 % by weight of the core and the tablets that release oxybutynin at a predetermined time of about 8 hours could be obtained when the tablets were coated to a weight gain of 20 % by weight of the core.
  • Example 2 One immediate release tablet, one tablet releasing oxybutynin at a predetermined time of about 4 hours and one tablet releasing oxybutynin at a predetermined time of about 8 hours were encapsulated in a hard gelatin capsule to provide an antispasmodic agent spaced drug delivery system of oxybutynin.
  • Example 2 One immediate release tablet, one tablet releasing oxybutynin at a predetermined time of about 4 hours and one tablet releasing oxybutynin at a predetermined time of about 8 hours were encapsulated in a hard gelatin capsule to provide an antispasmodic agent spaced drug delivery system of oxybutynin.
  • Example 2 One immediate release tablet, one tablet releasing oxybutynin at a predetermined time of about 4 hours and one tablet releasing oxybutynin at a predetermined time of about 8 hours were encapsulated in a hard gelatin capsule to provide an antispasmodic agent spaced drug delivery system of oxybutynin.
  • the antispasmodic agent spaced drug delivery system of the present invention was prepared as per the formula in Table 4 below.
  • the cores for the immediate release tablets, tablets releasing oxybutynin at a predetermined time of 4 hours and the tablets releasing oxybutynin at a predetermined time of 8 hrs were prepared by the method of preparation as described in example 1.
  • the immediate release tablet cores were not coated while the tablet cores for releasing the drug at a predetermined time intervals were coated using the coating composition given in Table 5 below.
  • the core tablets were coated in a conventional coating pan using a solution of ethyl cellulose and HPMC E50 in a mixture of dichloromethane and methanol.
  • the tablets that release oxybutynin at predetermined time of about 4 hours could be obtained when the tablets were coated to a weight gain of 13-14 % by weight of the core and the tablets that release oxybutynin at a predetermined time of about 8 hours could be obtained when the tablets were coated to a weight gain of 20% by weight of the core.
  • One immediate release tablet, one tablet releasing oxybutynin at a predetermined time of about 4 hours and one tablet releasing oxybutynin at a predetermined time of about 8 hours were encapsulated in a hard gelatin capsule.
  • the release profile for oxybutynin is recorded in Table 6 below.
  • Oxybutynin chloride (SPARC, Mumbai,) 10 mg capsules was used as the test product and Ditropan XL (Alza Corporation, USA, Lot no. TF 332, Exp. Date: May 2002) 10 mg tablets was used as the reference product.
  • the pharmacokinetics assessment was based on the plasma levels of oxybutynin chloride measured by blood sampling. Blood samples were obtained before dosing and at the following time points after dosing of both the reference and the test products at 2, 4, 5, 6, 7, 8, 9, 10, 10.5, 11, 11.5, 12, 12.5, 13, 14, 24, 36 and 48 hours.
  • the plasma concentration of oxybutynin was determined for samples collected at different time points and averaged over the six volunteers. The data is given in Table 7 below. The plasma concentration versus time profile is illustrated in Figure 1.

Abstract

L'asthme se définit comme un trouble inflammatoire chronique des voies aériennes de l'organe respiratoire. Elle se caractérise par une obstruction du courant aérien réversible entraînant la toux, la respiration sifflante, la légèreté thoracique et la dyspnée. L'inflammation de la paroi bronchique ainsi que l'augmentation de l'éosinophilie et d'autres produits inflammatoires des mastocytes et lymphocytes induisent également l'hyper-réponse des bronches de sorte qu'à leur tour, elles rétrécissent plus rapidement en réponse à une gamme importante de stimulus. Le médicament anti-asthmatique (Asmakure) possède des propriétés à usage pharmacologique prouvé permettant de soulager le rhume commun et la toux persistante et d'accroître l'immunité contre la récurrence de l'asthme. L'un des ingrédients, l'Adhatoda Vasica Nees (Basak) possède une action expectorante définie. Dans la bronchite aiguë, il permet un soulagement immédiat, notamment lorsque le crachat est épais et tenace. La dépression des terminaisons vagales soulage également l'irritation et le spasme des bronchioles.
PCT/IN2002/000203 2001-10-08 2002-10-08 Nouveau medicament anti-asthmatique (asmakure) a base d'herbes indigenes permettant de soigner l'asthme WO2003030920A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
MXPA04003002A MXPA04003002A (es) 2001-10-08 2002-10-08 Un sistema de administracion espacial de farmacos para agentes antiespasmodicos.
EP02800696A EP1450783A1 (fr) 2001-10-08 2002-10-08 Nouveau medicament anti-asthmatique (asmakure) a base d'herbes indigenes permettant de soigner l'asthme
CA002463168A CA2463168A1 (fr) 2001-10-08 2002-10-08 Nouveau medicament anti-asthmatique (asmakure) a base d'herbes indigenes permettant de soigner l'asthme
BR0213634-1A BR0213634A (pt) 2001-10-08 2002-10-08 Sistema de liberação de droga com ação retardada para um agente antiespasmódico
US10/492,070 US20040265381A1 (en) 2001-10-08 2002-10-08 Anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma
AU2002356418A AU2002356418A1 (en) 2001-10-08 2002-10-08 An antispasmodic agent spaced drug delivery system
HU0402611A HUP0402611A2 (hu) 2001-10-08 2002-10-08 Görcsoldó hatóanyag szakaszos leadására szolgáló rendszer
KR10-2004-7005049A KR20040045485A (ko) 2001-10-08 2002-10-08 항경련제가 간격을 두고 배치된 약물전달계
JP2003533951A JP2005510477A (ja) 2001-10-08 2002-10-08 抗痙攣薬の間隙をあけたドラッグデリバリーシステム

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN984MU2001 2001-10-08
IN984/MUM/2001 2001-10-08
INPCT/IN02/00107 2002-04-09
PCT/IN2002/000107 WO2002080887A2 (fr) 2001-04-10 2002-04-09 Composition a liberation par impulsion reglee dans le temps

Publications (2)

Publication Number Publication Date
WO2003030920A1 WO2003030920A1 (fr) 2003-04-17
WO2003030920A9 true WO2003030920A9 (fr) 2003-06-26

Family

ID=26324117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2002/000203 WO2003030920A1 (fr) 2001-10-08 2002-10-08 Nouveau medicament anti-asthmatique (asmakure) a base d'herbes indigenes permettant de soigner l'asthme

Country Status (5)

Country Link
EP (1) EP1450783A1 (fr)
JP (1) JP2005510477A (fr)
CN (1) CN1564691A (fr)
BR (1) BR0213634A (fr)
WO (1) WO2003030920A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5159094B2 (ja) * 2005-11-11 2013-03-06 旭化成ケミカルズ株式会社 活性成分の溶出を徐放性に制御する有核固形製剤
CA2648495C (fr) * 2006-04-26 2016-07-05 Alphapharm Pty Ltd Formulations a liberation controlee qui comprennent une ou plusieurs unites discretes non enrobees et une matrice a liberation retardee
AU2007313018A1 (en) * 2006-10-13 2008-04-24 Janssen Pharmaceutica N.V. Phenylalkyl carbamate compositions
GB201003731D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
ATE250929T1 (de) * 1997-05-30 2003-10-15 Osmotica Corp Mehrlagige osmosevorrichtung
US6248359B1 (en) * 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system

Also Published As

Publication number Publication date
CN1564691A (zh) 2005-01-12
WO2003030920A1 (fr) 2003-04-17
JP2005510477A (ja) 2005-04-21
BR0213634A (pt) 2004-11-30
EP1450783A1 (fr) 2004-09-01

Similar Documents

Publication Publication Date Title
EP0797435B1 (fr) Matrice a liberation regulee pour produits pharmaceutiques
AU2002314515B2 (en) Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
US20090124702A1 (en) Pharmaceutical Compositions of Metformin
US20060088594A1 (en) Highly compressible controlled delivery compositions of metformin
AU2002314515A1 (en) Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases
WO2009034541A9 (fr) Formes galéniques à libération contrôlée à base de trimétazidine
US20060257473A1 (en) Extended release tablet
US11324707B2 (en) Abuse-deterrent dosage forms containing esketamine
EP1377276B1 (fr) Composition a liberation par impulsion reglee dans le temps
KR100531065B1 (ko) 활성제 방출이 제어된 의약 제제
US20030099710A1 (en) Granule modulating hydrogel system
ES2321908T3 (es) Preparaciones farmaceuticas de liberacion prolongada independientemente del ph.
WO2003030920A9 (fr) Nouveau medicament anti-asthmatique (asmakure) a base d'herbes indigenes permettant de soigner l'asthme
US20030175353A1 (en) Oral controlled drug delivery system
MXPA05002136A (es) Forma de dosificacion de liberacion controlada de nitrofurantoina.
EP2010158B1 (fr) Formulations à libération contrôlée qui comprennent une ou plusieurs unités discrètes non enrobées et une matrice à libération retardée
US20040265381A1 (en) Anti-asthmatic drug (asmakure) from indigenous herbs to cure the disease asthma
KR20050114921A (ko) 방출제어형 약제학적 조성물
US20040228918A1 (en) Granule modulating hydrogel system
WO2008050188A2 (fr) Compositions pharmaceutiques d'alfuzosine à libération soutenue et son processus de préparation
WO2006136927A1 (fr) Preparation a liberation prolongee comprenant de la venlafaxine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PUBLISHED INTERNATIONAL SEARCH REPORT REPLACED BY CORRECT INTERNATIONAL SEARCH REPORT (3 PAGES) (WITH AN UPDATED VERSION OF THE PAMPHLET FRONT PAGE)

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/A/2004/003002

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004/02671

Country of ref document: ZA

Ref document number: 200402671

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 20028197976

Country of ref document: CN

Ref document number: 1020047005049

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 10492070

Country of ref document: US

Ref document number: 2463168

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003533951

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002800696

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002800696

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002800696

Country of ref document: EP